The Committee for Medicinal Products for Human Use (CHMP) decided that Sutent’ s benefits are greater than its risks for the treatment of unresectable and/ or metastatic malignant GIST after failure of imatinib mesilate treatment due to resistance or intolerance, and for the treatment of advanced and/ or metastatic RCC.